- Home
- BKV vs IDYA Comparison
BKV vs IDYA Comparison
Compare BKV & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKV
- IDYA
- Stock Information
- Founded
- BKV 2015
- IDYA 2015
- Country
- BKV United States
- IDYA United States
- Employees
- BKV N/A
- IDYA N/A
- Industry
- BKV Oil & Gas Production
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- BKV Energy
- IDYA Health Care
- Exchange
- BKV Nasdaq
- IDYA Nasdaq
- Market Cap
- BKV 1.8B
- IDYA 2.1B
- IPO Year
- BKV 2024
- IDYA 2019
- Fundamental
- Price
- BKV $22.79
- IDYA $25.12
- Analyst Decision
- BKV Strong Buy
- IDYA Strong Buy
- Analyst Count
- BKV 9
- IDYA 13
- Target Price
- BKV $28.11
- IDYA $51.36
- AVG Volume (30 Days)
- BKV 352.5K
- IDYA 1.0M
- Earning Date
- BKV 08-12-2025
- IDYA 08-05-2025
- Dividend Yield
- BKV N/A
- IDYA N/A
- EPS Growth
- BKV N/A
- IDYA N/A
- EPS
- BKV N/A
- IDYA N/A
- Revenue
- BKV $756,795,000.00
- IDYA $7,000,000.00
- Revenue This Year
- BKV $49.49
- IDYA $101.44
- Revenue Next Year
- BKV $11.90
- IDYA $263.37
- P/E Ratio
- BKV N/A
- IDYA N/A
- Revenue Growth
- BKV 13.79
- IDYA N/A
- 52 Week Low
- BKV $15.00
- IDYA $13.45
- 52 Week High
- BKV $26.78
- IDYA $40.74
- Technical
- Relative Strength Index (RSI)
- BKV 64.23
- IDYA 60.16
- Support Level
- BKV $21.09
- IDYA $23.57
- Resistance Level
- BKV $21.61
- IDYA $25.11
- Average True Range (ATR)
- BKV 0.65
- IDYA 1.12
- MACD
- BKV 0.29
- IDYA 0.02
- Stochastic Oscillator
- BKV 95.00
- IDYA 81.23
About BKV BKV Corporation Common Stock
BKV Corp is a growth-driven energy company. Its core business is production of natural gas from its owned and operated upstream businesses. It operates in four business lines: natural gas production, natural gas gathering, processing and transportation (natural gas midstream business), power generation and carbon capture, utilization, and sequestration (CCUS).
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.